➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKinsey
Colorcon
Boehringer Ingelheim
Merck

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Details for Biologics License Application: 203313

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for BLA: 203313
Tradename:RYZODEG 70/30
Applicant:Novo
Ingredient:insulin aspart; insulin degludec
Patents:8
Approval Date:Mar 07, 2016

US Patents for BLA: 203313

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2021-01-05 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DE) 2023-08-05 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordiks A/S (Bagsvaerd, DK) 2024-10-21 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2021-01-05 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2024-10-21 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
McKesson
Mallinckrodt
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.